*Group B increases representation of participants who are homozygous for APOE4 to ~2x that of the general AD population.

AD, Alzheimer’s disease; APOE4, apolipoprotein E4; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; SC, subcutaneous.